Search Results

You are looking at 91 - 100 of 515 items for :

  • "Adjuvant therapy" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Ten Years of Progress in Melanoma

John A. Thompson

-positives. PET/CT may be more useful than conventional CT in the workup of patients who have relatively high pretest probabilities of occult metastatic disease (eg, patients with stage IIIB and IIIC melanoma). Treatment Adjuvant Therapy High

Full access

Clinical Consequences of Altering the Definition of HER2-Positive Breast Cancer to Exclude Group 2, HER2-Negative Disease

Steven Sorscher

HER2 copy number is less than 4 signals/cell is that….” 2 Based on the pre-2018 ASCO/CAP HER2 classification, whether being used as adjuvant therapy or therapy for metastatic HER2-positive disease, the FDA-approved anti-HER2 therapies offer truly

Full access

Validation of the PREDICT Prognostication Tool in US Patients With Breast Cancer

Nickolas Stabellini, Lifen Cao, Christopher W. Towe, Megan E. Miller, Artur H. Sousa-Santos, Amanda L. Amin, and Alberto J. Montero

,700 breast cancer–related deaths are expected. 2 Due to steady progress in early breast cancer diagnosis and treatment, 5-year overall survival (OS) continues to improve. 3 Accurate estimates of survival and the impact of different adjuvant therapies in

Full access

Systemic Management of Colorectal Cancer

Wells A. Messersmith

treatment with the best chance of success. Adjuvant Therapy Although 11 agents have been approved by the FDA for CRC, only 3 are used in the adjuvant setting (fluorouracil [5-FU], capecitabine, and oxaliplatin) and only 2 (cetuximab and panitumumab

Full access

CRE24-040: Gluteal Metastasis of Intrahepatic Cholangiocarcinoma: Clinical Case and Literature Review

Natalia de la Puente Mota, Yolanda Gómez Fandiño, Francisco Javier Anguita Ramos, María López López, Mariaclaudia Ocharán Puell, Beatriz Carnero López, Jorge González Ramírez, Adriana Fernández García, and José Conde Vales

diagnosed with intrahepatic cholangiocarcinoma three years prior and was treated with resection and adjuvant therapy involving chemotherapy and radiotherapy. He was referred to the general surgery outpatient clinic by his oncologist for the excision of a

Full access

HSR20-102: Quality Outcomes in Colon Cancer

Michelle Moskal and Neeharika S. Makani

, only 6.3% of high risk stage II and 45.5% of stage III patients received adjuvant therapy. Data showed 100% compliance with initiation of adjuvant 5-FU based chemotherapy within 12 weeks post surgery, which is recommended in high risk stage II and III

Full access

Highlights of the NCCN Oncology Research Program

) colorectal cancer who have received prior treatment with a fluoropyrimidine (5-FU or capecitabine) and oxaliplatin or who have experienced a recurrence within 12 months of adjuvant therapy with a regimen that included oxaliplatin. For study purposes, a cycle

Full access

HSR23-103: Pancreatic Cancer: The Impact of Early Connectivity and Coordination of Care on Retention and Time to Treat

Nicole Nardella, Matt Adams, Anjali Mahapatra, Diana Castillo, Sarah Hoffe, Dae Won Kim, Jason Fleming, and Pamela Hodul

adjuvant therapy (n=33). Of those that were resectable, borderline resectable, or locally advanced (n=191), 76% (145/191) had coordinated care secondary to their FC call; 68% of patients saw multiple interdisciplinary providers, with 25% occurring on the

Full access

HSR22-150: Lymph Node Evaluation of Post-Neoadjuvant Rectal Resection Specimens in Rectal Carcinoma

Saman S Karimi and Maria Gonzalez

determine the number of positive lymph nodes as an independent prognostic indicator in Stage II colorectal carcinoma, which prompts adjuvant therapy in these patients. This study aimed to assess the average number of lymph nodes in post-neoadjuvant rectal

Full access

BPI20-014: Clinical Pathway and Education Implementation to Support Guideline Adherent Breast Cancer Care for Rural Women Under Age 50

Robin M. Lally, Elizabeth Reed, and Roksana Zak

-treatment assessments, consultations, considerations, neoadjuvant and adjuvant therapy and survivorship care. Oncology provider survey return rate was 25%. Results indicated satisfaction but changes needed to pathway design and content. Modified pathways were